Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.

Trial Details

NCT ID
NCT05753618
Phase
PHASE4
Sponsor
Ottawa Hospital Research Institute
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Omission of Granulocyte Colony-Stimulating Factor (G-CSF)
Locations (sample)
  • Kingston, Ontario, Canada|44.22976,-76.48098
  • Oshawa, Ontario, Canada|43.90012,-78.84957
  • Ottawa, Ontario, Canada|45.41117,-75.69812

Key Eligibility Criteria

  • Patients with early-stage or locally-advanced breast cancer receiving neoadjuvant or adjuvant DD-AC/T chemotherapy requiring primary febrile neutro…
  • Able to provide verbal consent
  • Able to complete questionnaires in English or French

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →